<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859729</url>
  </required_header>
  <id_info>
    <org_study_id>pVAX/rhPSA -EP 2006</org_study_id>
    <secondary_id>EudraCT # 2006-001128-38</secondary_id>
    <nct_id>NCT00859729</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer</brief_title>
  <official_title>DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients With Relapsed Prostate Cancer. A Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cyto Pulse Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the feasibility and safety of vaccination with increasing doses of
      xenogenic DNA administered intradermally in combination with electroporation in patients with
      relapse of prostate cancer. The DNA encodes prostate specific antigen (PSA) from Rhesus
      Macaque (Macaca mulatta), a protein that is 89% homologous to human PSA. The study will also
      assess the safety and functionality of the DERMA VAX™ (Cyto Pulse Sciences) DNA vaccine
      delivery system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the feasibility and safety of escalating doses of pVAXrcPSAv53l DNA vaccine, administered intradermally in combination with electroporation in patients with relapse of prostate cancer.</measure>
    <time_frame>From start of treatment to 30 days (safety) or up to 12 months (immunological &amp; clinical) post last vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and functionality of the DERMA VAX™ in vivo electroporation DNA vaccine delivery system.</measure>
    <time_frame>From start of treatment to 30 days (safety) or up to 12 months (immunological &amp; clinical) post last vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PSA-specific immune response induced by the vaccine.</measure>
    <time_frame>From start of treatment to 30 days (safety) or up to 12 months (immunological &amp; clinical) post last vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify an anti-tumor effect of the vaccine.</measure>
    <time_frame>From start of treatment to 30 days (safety) or up to 12 months (immunological &amp; clinical) post last vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 µg DNA/dose, 3 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 µg DNA/dose, 3 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 µg DNA/dose, 3 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 µg DNA/dose, 3 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal dose to be determined, 6 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pVAXrcPSAv53l (DNA encoding rhesus PSA)</intervention_name>
    <description>5 doses, 4 weeks apart</description>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_label>Cohort IV</arm_group_label>
    <arm_group_label>Cohort V</arm_group_label>
    <other_name>rhPSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DERMA VAX™ intradermal DNA delivery system</intervention_name>
    <description>in vivo electroporation is applied after each DNA injection</description>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_label>Cohort IV</arm_group_label>
    <arm_group_label>Cohort V</arm_group_label>
    <other_name>Derma Vax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients. Age &gt;18 years.

          -  HLA-A*0201 positive.

          -  Histologically confirmed prostate cancer.

          -  Minimum two (2) and maximum four (4) years after treatment with curative or salvage
             radiotherapy.

          -  Serum testosterone within normal range.

          -  Increasing PSA from a previous reference value on two (2) consecutive occasions at
             least one month apart and with a minimum of 2 ng/mL above nadir.

          -  PSA doubling time is one (1) year or less.

          -  No evidence of metastatic prostate cancer.

          -  Karnofsky performance status ≥ 80.

          -  Adequate organ function:

               -  AST and ALT ≤ 2.0 x upper limit of normal (ULN); total serum bilirubin ≤ 1.5 x
                  ULN

               -  Calcium ≤ 2.6 mmol/L, serum creatinine ≤ 1.5 x ULN

               -  Hb ≥ 100 g/L; absolute leukocyte count ≥ 3.0 x 109 /L; platelets ≥100 x 109 /L

          -  Life expectancy ≥ 12 months.

          -  Swedish or English speaking subjects only.

          -  Written informed consent (subjects must be capable of providing their own informed
             consent).

        Exclusion Criteria:

          -  Previous ablation of testis.

          -  Radiologic evidence of metastatic disease.

          -  Prior chemotherapy or investigational therapy/agents within 4 weeks.

          -  Active bacterial, viral or fungal infection.

          -  Carrier of HIV, HBV, or HCV.

          -  Immunosuppressed (post splenectomy, post stem cell transplantation) or on
             immunosuppressive therapy other than inhaled or replacement corticosteroids.

          -  Any other major illness or peripheral blood vein status that, in the investigator's
             judgement, will substantially increase the risk associated with sampling or
             participation in this study.

          -  Subjects with cardiac demand pacemakers.

          -  Any reason why, in the opinion of the investigator, the patient should not
             participate.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Yachnin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, University Hospital Uppsala</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, University Hospital Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Jeffrey Yachnin</investigator_full_name>
    <investigator_title>Prinicple Investigator</investigator_title>
  </responsible_party>
  <keyword>DNA</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Electroporation</keyword>
  <keyword>xenogenic</keyword>
  <keyword>PSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

